Flamel
Technology (Nasdaq: FLML) reported that the Food and Drug
Administration approved rival Fresenius Kabi's New Drug Application for
neostigmine methylsulfate, which Flamel sells as Bloxiverz. Shares of the specialty pharmaceutical plummeted $6.97 to close at $11.50.
Flamel's Bloxiverz may face competition
January 14, 2015 at 16:58 PM EST
